Cytosorbents Investor Relations Material

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. The Company's business strategy is to develop its novel platform technology that enables it to manufacture and sell a broad range of products used in hemodialysis services, emergency medicine, surgery and clinics. The Company’s clinical trials are focused on expanding applications for cytotoxic drugs such as chemotherapy for cancer patients as well as immune cell therapies for autoimmune diseases such as endocrine disorders, infectious disease and immunodeficiencies; regenerative medicine; organ preservation prior to transplantation; tissue repair grafting; acute care stabilization procedures allowing time for surgical interventions; and drug discovery applications for target validation, screening of potential new agents or natural compounds from plants or marine sources.